Shoseyov D[au] - Search Results

Year	Number of Results
1992	1
1993	2
1997	2
1998	3
1999	1
2000	1
2001	2
2002	10
2003	2
2004	2
2005	5
2006	5
2007	1
2008	2
2009	3
2010	5
2011	7
2012	4
2013	8
2014	3
2015	9
2016	10
2017	7
2018	3
2019	2
2020	1
2021	6
2022	0

1

Could you please pass the salt?

Shoseyov D, Cohen-Cymberknoh M, Kerem E. Shoseyov D, et al. Am J Respir Crit Care Med. 2011 Jun 1;183(11):1444-6. doi: 10.1164/rccm.201102-0351ED. Am J Respir Crit Care Med. 2011. PMID: 21642252 No abstract available.

2

Increasing Vitamin D Serum Levels Is Associated With Reduced Pulmonary Exacerbations in Patients With Cystic Fibrosis.

Abu-Fraiha Y, Elyashar-Earon H, Shoseyov D, Cohen-Cymberknoh M, Armoni S, Kerem E, Wilschanski M. Abu-Fraiha Y, et al. Among authors: shoseyov d. J Pediatr Gastroenterol Nutr. 2019 Jan;68(1):110-115. doi: 10.1097/MPG.0000000000002126. J Pediatr Gastroenterol Nutr. 2019. PMID: 30095576

3

Laryngeal obstruction in congenital plasminogen deficiency.

Cohen J, Cohen S, Cymberknoh MC, Gross M, Hirshoren N, Shoseyov D. Cohen J, et al. Among authors: shoseyov d. Pediatr Pulmonol. 2012 Sep;47(9):923-5. doi: 10.1002/ppul.22522. Epub 2012 Feb 10. Pediatr Pulmonol. 2012. PMID: 22328462 Review.

4

Ethical Dilemma: Elexacaftor-Tezacaftor-Ivacaftor or Lung Transplantation in Cystic Fibrosis and End-Stage Lung Disease?

Breuer O, Shoseyov D, Koretz S, Alyan N, Reiter J, Cohen-Cymberknoh M, Wexler I, Kerem E. Breuer O, et al. Among authors: shoseyov d. Chest. 2021 Oct 7:S0012-3692(21)03846-0. doi: 10.1016/j.chest.2021.08.073. Online ahead of print. Chest. 2021. PMID: 34506793 Review.

5

NKp46 regulates allergic responses.

Ghadially H, Horani A, Glasner A, Elboim M, Gazit R, Shoseyov D, Mandelboim O. Ghadially H, et al. Among authors: shoseyov d. Eur J Immunol. 2013 Nov;43(11):3006-16. doi: 10.1002/eji.201343388. Epub 2013 Aug 21. Eur J Immunol. 2013. PMID: 23878025 Free PMC article.

6

Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life.

Cohen-Cymberknoh M, Shoseyov D, Kerem E. Cohen-Cymberknoh M, et al. Among authors: shoseyov d. Am J Respir Crit Care Med. 2011 Jun 1;183(11):1463-71. doi: 10.1164/rccm.201009-1478CI. Epub 2011 Feb 17. Am J Respir Crit Care Med. 2011. PMID: 21330455 Review.

7

Control of phospholipase A2 activities for the treatment of inflammatory conditions.

Yedgar S, Cohen Y, Shoseyov D. Yedgar S, et al. Among authors: shoseyov d. Biochim Biophys Acta. 2006 Nov;1761(11):1373-82. doi: 10.1016/j.bbalip.2006.08.003. Epub 2006 Aug 3. Biochim Biophys Acta. 2006. PMID: 16978919 Review.

8

Primary ciliary dyskinesia: prospects for new therapies, building on the experience in cystic fibrosis.

Amirav I, Cohen-Cymberknoh M, Shoseyov D, Kerem E. Amirav I, et al. Among authors: shoseyov d. Paediatr Respir Rev. 2009 Jun;10(2):58-62. doi: 10.1016/j.prrv.2008.11.003. Epub 2009 Apr 9. Paediatr Respir Rev. 2009. PMID: 19410203 Review.

9

Ivacaftor in People with Cystic Fibrosis and a 3849+10kb C→T or D1152H Residual Function Mutation.

Kerem E, Cohen-Cymberknoh M, Tsabari R, Wilschanski M, Reiter J, Shoseyov D, Gileles-Hillel A, Pugatsch T, Davies JC, Short C, Saunders C, DeSouza C, Sullivan JC, Doyle JR, Chandarana K, Kinnman N. Kerem E, et al. Among authors: shoseyov d. Ann Am Thorac Soc. 2021 Mar;18(3):433-441. doi: 10.1513/AnnalsATS.202006-659OC. Ann Am Thorac Soc. 2021. PMID: 33095038 Clinical Trial.

10

Ataluren for the treatment of cystic fibrosis.

Shoseyov D, Cohen-Cymberknoh M, Wilschanski M. Shoseyov D, et al. Expert Rev Respir Med. 2016 Apr;10(4):387-391. doi: 10.1586/17476348.2016.1150181. Epub 2016 Feb 24. Expert Rev Respir Med. 2016. PMID: 26840186

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results